Amy Rosenberg (121 results)

Condition: Very Good. Item in good condition. Textbooks may not include supplemental items i.e. CDs, access codes etc.

Condition: As New. Rosenberg, Amy (illustrator). Like New condition. A near perfect copy that may have very minor cosmetic defects.

Condition: As New. Rosenberg, Amy (illustrator). Like New condition.

Condition: Very Good. Rosenberg, Amy (illustrator). Used book that is in excellent condition. May show signs of wear or have minor defects.

Hardcover. Condition: Very Good. No Jacket. Rosenberg, Amy (illustrator). May have limited writing in cover pages. Pages are unmarked. ~ ThriftBooks: Read More, Spend Less.

Paperback. Condition: Very Good. No Jacket. May have limited writing in cover pages. Pages are unmarked. ~ ThriftBooks: Read More, Spend Less.

Paperback. Condition: Very Good. Ship within 24hrs. Satisfaction 100% guaranteed. APO/FPO addresses supported.

Hardcover. Glossy pictorial hardcover in very good clean condition. No dust jacket. Charming illustrations and words provide an alphabetical array. End of book shows all the letters in upper and lower case print.

Hardcover. Condition: Fine. No Jacket. Rosenberg, Amy (illustrator). 1st Edition. Gift quality hardcover with sharp tips and spine ends. No names in space provided on fep. 26 pp text crisp and unmarked. A journal to keep at Christmas.

Paperback. Condition: Very Good+. commentary by Harry Braverman. This is a special 128-page issue of Monthly Review An Independent Socialist Magazine Volume 28 #3 July-August 1976. some light stains on rear cover. 124 pages; 5 1/2 x 8 1/4 ".

Paperback. Condition: Brand New. 66 pages. 9.00x6.00x0.17 inches. In Stock.

Hardcover. Condition: Fine. Dust Jacket Condition: Fine. Amy Halperin(Jacket Design) (illustrator). First Edition. Keepers of the Hidden Ways by Joel Rosenberg (First Edition) A sharp, tight, copy. A bright dust jacket. Not price-clipped. First printing with a full number line 1- 10. BOOK.

Condition: Good. Book is in Used-Good condition. Pages and cover are clean and intact. Used items may not include supplementary materials such as CDs or access codes. May show signs of minor shelf wear and contain limited notes and highlighting.

Condition: As New. Unread book in perfect condition.

Hardcover. Condition: Good. No Jacket. Mooney, Jeannie (illustrator). Item is in good condition. Some moderate creases and wear. This item may not come with CDs or additional parts including access codes for textbooks. This may not have a dust jacket. Might be an ex-library copy and contain writing/highlighting. Photos are stock pictures and not of the actual item.

Paperback. Condition: Good.

Paperback. Condition: Very Good. Pages unmarked, mild wear.

paperback. Condition: New. Language: ENG.

Paperback. Condition: Very Good. First Edition. 98 pages. Features: Cool World - Drawing a line between comics and art at the Vancouver Art Gallery; New Painting - Chris Flodberg, Lisa Wood, Dougal Graham; In Retrospect - Aganetha Dyck and Daphne Odjig; Featured Artists - Dana Claxton, Greg Girard, Ken Dalgarno, Margaret Shelton; and more. Clean and unmarked with light wear. A quality copy.

staple binding. Condition: Fine. cm 21x21; pp. 22; BW ills.; staple binding.

Encuadernación de tapa blanda. Condition: Muy bien. Dust Jacket Condition: Muy bien. Issue edited by Tim Griffin. Essays "Passages: Robert Rosenblum on Tom Wesselmann," by Robert Rosenblum; "Passages: Thomas Lawson on Gretchen Bender," by Thomas Lawson; "Books: Keith Sanborn on Guy Debord," by Keith Sanborn; "Film: James Quandt on 'Cinévardaphoto,'" by James Quandt; "On Site: Carol Armstrong on the Barnes Foundation," by Carol Armstrong; "Media: Christopher Bollen on Courtroom Drawings," by Christopher Bollen; "News: Steven Henry Madoff on the Walker Art Center," by Steven Henry Madoff; "Top Ten," by Kehinde Wiley; "Please Recycle: The Art of Kelley Walker," by Tim Griffin; "Russian Front: The Moscow Biennale," by John Kelsey; "1000 Words: Spencer Finch," by Daniel Birnbaum; "Artist Curates: Personal Affects," by T.J. Wilcox; "Vocational Education: An Interview with Lucrecia Martel," by Amy Taubin; "Openings: Hans Op de Beeck," by Martin Herbert. Reviews by Jack Bankowsky, Isabelle Graw, David Deitcher, Lynne Cooke, Barry Schwabsky, Michael Wilson, Jan Avgikos, Donald Kuspit, Martha Schwendener, Nell McClister, Johanna Burton, Elizabeth Schambelan, Frances Richard, Karen Rosenberg, Suzanne Hudson, Brian Sholis, Jeffrey Kastner, Jonathan Raymond, Tom Breidenbach, David Carrier, Michael Odom, Glen Helfand, Bruce Hainley, Jan Tumlir, Christopher Miles, Maxine Swann, Pablo Llorca, Filippo Romeo, Giorgio Verzotti, Marco Meneguzzo, Guitemie Maldonado, Sabine B. Vogel, Astrid Wege, Jennifer Allen, Michael Archer, Rachel Withers, David Spalding. Cover: Kelley Walker.

VI, 331 p. Hardcover. Versand aus Deutschland / We dispatch from Germany via Air Mail. Einband bestoßen, daher Mängelexemplar gestempelt, sonst sehr guter Zustand. Imperfect copy due to slightly bumped cover, apart from this in very good condition. Stamped. AAPS Advances in the Pharmaceutical Sciences Series, 32. Sprache: Englisch.

Taschenbuch. Condition: Neu. Druck auf Anfrage Neuware -'Biobetters: Protein Engineering to Approach the Curative' discusses the optimization of protein therapeutic products for treatment of human diseases. It is based on the fact that though numerous important therapeutic protein products have been developed for life threatening and chronic diseases that possess acceptable safety and efficacy profiles, these products have generally not been reexamined and modified for an improved clinical performance, with enhancements both to safety and efficacy profiles. Advances in protein engineering, coupled with greatly enhanced understanding of critical product quality attributes for efficacy and safety, make it possible to optimize predecessor products for clinical performance, thereby enhancing patient quality of life and with the potential for great savings in health care costs. Yet despite such knowledge, there is little movement towards such modifications. This book examines engineering protein therapeutic products such that they exhibit an optimal, not just an adequate, clinical performance profile. Two product classes, therapeutic enzymes for lysosomal storage diseases (enzyme replacement therapies, ERT) and monoclonal antibodies (mAbs), are used as examples of what modifications to such proteins could be made to enhance clinical performance, 'closer to a cure' as it were. For ERT, the key to optimizing clinical performance is to ensure the ERT is endowed with moieties that target the protein to the relevant target tissue. Thus, for Gaucher Disease, our best example of how to optimize an ERT to address a disease that manifests in specific target tissues (macrophages and monocytes), the enzyme has been extensively modified to target macrophages. For diseases such as Pompe Disease, largely a disorder of muscle, optimal performance of ERT will depend on endowing the enzyme with the ability to be taken up via the Mannose 6 Phosphate Receptor, and so one of the chapters in the book will discuss such approaches. Moreover, a major failure of biotechnology based products is to gain access to the CNS, a key target tissue in numerous diseases. Thus, a chapter has been devoted to strategies to access the CNS. Additionally, immune responses to therapeutic proteins can be highly problematic, eliminating the efficacy of life saving or highly effective protein therapeutics. This is especially poignant in the case of Pompe Disease wherein great improvement in muscle strength and functionality is lost following development of an immune response to the ERT with consequent patient deterioration and death. Thus, a chapter regarding protein engineering, as well as other non-clinical approaches to diminishing immunogenicity is a valuable part of the book. Monoclonal antibodies (mAbs) can be engineered to bind targets relevant to a wide variety of diseases; binding affinity, however, is only part of the equation and one of the chapters will present a molecular assessment approach that balances affinity with pharmacokinetics and manufacturability. As with other proteins immunogenicity can be problematic, being responsible for loss of efficacy of anti-TNF mAbs, often after prolonged successful treatment. The authors will also share their perspective on the consequences of physico-chemical modifications occurring to mAbs once they reach the circulation or their target, a research area open to further development from a protein engineering as well as analytical perspective. This book will also discuss novel platforms for protein therapeutics, technologies that exceed mAbs with respect to potency, and hence, potentially efficacy. These platforms consist largely of repeat domain proteins with very high affinity for their target ligands, but while potentially more efficacious, immunogenicity may be a major problem limiting use. The economics surrounding the issue of biobetters is another high-profile issue - this final chapter will explore the incentives and disincentives for developing biobetters and consider in 396 pp. Englisch.

Buch. Condition: Neu. Druck auf Anfrage Neuware -'Biobetters: Protein Engineering to Approach the Curative' discusses the optimization of protein therapeutic products for treatment of human diseases. It is based on the fact that though numerous important therapeutic protein products have been developed for life threatening and chronic diseases that possess acceptable safety and efficacy profiles, these products have generally not been reexamined and modified for an improved clinical performance, with enhancements both to safety and efficacy profiles. Advances in protein engineering, coupled with greatly enhanced understanding of critical product quality attributes for efficacy and safety, make it possible to optimize predecessor products for clinical performance, thereby enhancing patient quality of life and with the potential for great savings in health care costs. Yet despite such knowledge, there is little movement towards such modifications. This book examines engineering protein therapeutic products such that they exhibit an optimal, not just an adequate, clinical performance profile. Two product classes, therapeutic enzymes for lysosomal storage diseases (enzyme replacement therapies, ERT) and monoclonal antibodies (mAbs), are used as examples of what modifications to such proteins could be made to enhance clinical performance, 'closer to a cure' as it were. For ERT, the key to optimizing clinical performance is to ensure the ERT is endowed with moieties that target the protein to the relevant target tissue. Thus, for Gaucher Disease, our best example of how to optimize an ERT to address a disease that manifests in specific target tissues (macrophages and monocytes), the enzyme has been extensively modified to target macrophages. For diseases such as Pompe Disease, largely a disorder of muscle, optimal performance of ERT will depend on endowing the enzyme with the ability to be taken up via the Mannose 6 Phosphate Receptor, and so one of the chapters in the book will discuss such approaches. Moreover, a major failure of biotechnology based products is to gain access to the CNS, a key target tissue in numerous diseases. Thus, a chapter has been devoted to strategies to access the CNS. Additionally, immune responses to therapeutic proteins can be highly problematic, eliminating the efficacy of life saving or highly effective protein therapeutics. This is especially poignant in the case of Pompe Disease wherein great improvement in muscle strength and functionality is lost following development of an immune response to the ERT with consequent patient deterioration and death. Thus, a chapter regarding protein engineering, as well as other non-clinical approaches to diminishing immunogenicity is a valuable part of the book. Monoclonal antibodies (mAbs) can be engineered to bind targets relevant to a wide variety of diseases; binding affinity, however, is only part of the equation and one of the chapters will present a molecular assessment approach that balances affinity with pharmacokinetics and manufacturability. As with other proteins immunogenicity can be problematic, being responsible for loss of efficacy of anti-TNF mAbs, often after prolonged successful treatment. The authors will also share their perspective on the consequences of physico-chemical modifications occurring to mAbs once they reach the circulation or their target, a research area open to further development from a protein engineering as well as analytical perspective. This book will also discuss novel platforms for protein therapeutics, technologies that exceed mAbs with respect to potency, and hence, potentially efficacy. These platforms consist largely of repeat domain proteins with very high affinity for their target ligands, but while potentially more efficacious, immunogenicity may be a major problem limiting use. 378 pp. Englisch.

Couverture illustrée. Condition: Comme neuf. Edition originale. Zurich, Edition EcartPublications (John Armleder, Amy Granat, Mai-Thu Perret) et JRP Ringier, 2007, Coffret cartonné (17,5 x 9,5 x 27 cm) contenant 32 livres brochés (480 pp.). Coffret de 32 livres d'artistes en hommage à Steven Parrino, conçus sur le modèle des comic books américains. Edition limitée à 250 exemplaires. Chaque volume est réalisé par un artiste différent, lié d?une certaine manière à Steven Parrino, par des projets et des échanges, par amitié, par inspiration réciproque. Black Noise célèbre, au travers d'un format que Steven Parrino affectionnait, une culture qui lui était proche. Les artistes invités n?ont eu d?autres contraintes que le format et le titre de l?ensemble de la publication. Certains évoquent directement la personnalité de Steven Parrino, d?autres proposent un projet moins directement référentiel. Avec Rich Aldrich, John Armleder, Fia Backström, Sophie Bernhard, Peter Coffin, Philippe Decrauzat, Vidya Gastaldon & Fabrice Stroun, Gabrielle Giattino & Sarah Turner, Janine Gordon, Kim Gordon, Amy Granat, Drew Heitzler & Flora Wiegman, Jutta Koether, Alix Lambert, Balthazar Lovay, Brendan Majewski, Christian Marclay, Mass, John Miller, Thurston Moore, Olivier Mosset, Chuck Nanney, Genesis P-Orridge, Mai-Thu Perret, Carissa Rodriguez, Aura Rosenberg, Michael Scott, John Terhorst, Blair Thurman, John Tremblay, Elizabeth Valdez, Joan Wallace. Etat Neuf / As new.